Dr. Linas is a national leader in hepatitis-C virus (HCV) infection and HCV/HIV co-infection comparative- and cost-effectiveness research using computational biology, clinical epidemiology and clinical economics methods. Dr. Linas has an excellent track record of productivity, ample funding from the NIH and CDC, and a growing core of successful trainees. Dr. Linas directs the HIV/HCV core of the Center for Health Economics of Treatment Interventions for Substance Use Disorders, HCV, and HIV, funded by the National Institute on Drug Abuse (NIDA) in collaboration with Cornell, U Penn and Miami.
- Associate Professor, Epidemiology, Boston University School of Public Health
- New York University School of Medicine, MD
- Harvard School of Public Health, MPH
- Yale University, BA
- Published on 9/28/2023
Tin Y, Castry M, Bowers-Sword R, Shantharam S, Aldridge A, Zarkin GA, Starbird L, Linas BP, Barocas JA, Morgan JR. Establishing a Protocol for Determining the Costs of an Integrated Set of Evidence-based Practices Aimed at Reducing Opioid Overdose Deaths. J Addict Med. 2023 Sep 28. PMID: 37768777.
- Published on 9/26/2023
Frimpong JA, Parish CL, Feaster DJ, Gooden LK, Nelson MC, Matheson T, Siegel K, Haynes L, Linas BP, Assoumou SA, Tross S, Kyle T, Liguori TK, Toussaint O, Annane D, Metsch LR. A study protocol for Project I-Test: a cluster randomized controlled trial of a practice coaching intervention to increase HIV testing in substance use treatment programs. Trials. 2023 Sep 26; 24(1):609. PMID: 37749635.
- Published on 9/5/2023
Flam-Ross JM, Marsh E, Weitz M, Savinkina A, Schackman BR, Wang J, Madushani RWMA, Morgan JR, Barocas JA, Walley AY, Chrysanthopoulou SA, Linas BP, Assoumou SA. Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder. JAMA Netw Open. 2023 Sep 05; 6(9):e2329583. PMID: 37703018.
- Published on 8/28/2023
Zang X, Walley AY, Chatterjee A, Kimmel SD, Morgan JR, Murphy SM, Linas BP, Nolen S, Reilly B, Urquhart C, Schackman BR, Marshall BDL. Changes to opioid overdose deaths and community naloxone access among Black, Hispanic and White people from 2016 to 2021 with the onset of the COVID-19 pandemic: An interrupted time-series analysis in Massachusetts, USA. Addiction. 2023 Aug 28. PMID: 37640687.
- Published on 6/28/2023
Chen S, Walt G, Aldrich A, McAlearney AS, Linas B, Amuchi B, Freedman DA, Goddard-Eckrich D, Gibson E, Hartman Ms J, Bosak J, Lunze K, Jones L, Christopher M, Salsberry P, Jackson R, Back S, Drainoni ML, Walker DM. A Qualitative Study of Health Equity's Role in Community Coalition Development. Health Educ Behav. 2023 Jun 28; 10901981231179755. PMID: 37376998.
- Published on 6/28/2023
Frimpong JA, Parish C, Feaster DJ, Gooden LK, Matheson T, Haynes L, Linas BP, Assoumou SA, Tross S, Kyle T, Nelson CM, Liguori TK, Toussaint O, Siegel K, Annane D, Metsch LR. A study protocol for Project I-Test: a cluster randomized controlled trial of a practice coaching intervention to increase HIV testing in substance use treatment programs. Res Sq. 2023 Jun 28. PMID: 37461594.
- Published on 6/8/2023
Sowah LA, Smeaton L, Brates I, Bhattacharya D, Linas B, Kreter B, Wagner-Cardoso S, Solomon S, Sulkowski M, Robbins GK. Perspectives on Adherence From the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach With 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment. Clin Infect Dis. 2023 Jun 08; 76(11):1959-1968. PMID: 36694361.
- Published on 5/29/2023
Hahn JA, Ngabirano C, Fatch R, Emenyonu NI, Cheng DM, Adong J, Tumwegamire A, Terrault NA, Linas BP, Jacobson KR, Muyindike WR. Safety and tolerability of isoniazid preventive therapy for tuberculosis for persons with HIV with and without alcohol use. AIDS. 2023 Aug 01; 37(10):1535-1543. PMID: 37260251.
- Published on 5/2/2023
Barocas JA, Nall SK, Axelrath S, Pladsen C, Boyer A, Kral AH, Meehan AA, Savinkina A, Peery D, Bien M, Agnew-Brune C, Goldshear J, Chiang J, Linas BP, Gonsalves G, Bluthenthal RN, Mosites E. Population-Level Health Effects of Involuntary Displacement of People Experiencing Unsheltered Homelessness Who Inject Drugs in US Cities. JAMA. 2023 May 02; 329(17):1478-1486. PMID: 37036716.
- Published on 4/3/2023
Jawa R, Tin Y, Nall S, Calcaterra SL, Savinkina A, Marks LR, Kimmel SD, Linas BP, Barocas JA. Estimated Clinical Outcomes and Cost-effectiveness Associated With Provision of Addiction Treatment in US Primary Care Clinics. JAMA Netw Open. 2023 Apr 03; 6(4):e237888. PMID: 37043198.
View 151 more publications: View full profile at BUMC